Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-12-21, Stock:NVS, The news for the past five days is as follows:
2021-12-14: NEWS1: Molecular Partners Inks License Deal With Novartis For $580M.
2021-12-15: NEWS1: VanEck Pharmaceutical ETF Buys Sanofi SA, AstraZeneca PLC, AbbVie Inc.
2021-12-16: NEWS1: Novartis AG -- Moody's says Novartis' announced share buybacks do not materially affect its credit profile.NEWS2: Novartis to Spend Bulk of Roche Windfall on Buyback, Not M&A.NEWS3: Novartis Launches New Share Buyback Program Of Up To $15B.NEWS4: Buyback Bonanza: Novartis May Snap Up $15 Billion of Stock.NEWS5: Premarket Movers Thursday After Bank of England Rate Hike.NEWS6: UPDATE 1-Cash-flush Novartis launches new share buyback of up to $15 bln.NEWS7: Cash-flush Novartis launches new share buyback of up to $15 billion.NEWS8: Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline.NEWS9: European Stock Futures Higher; Fed Decision, ECB and BOE Meetings in Focus.
2021-12-17: nan
2021-12-20: NEWS1: Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA.NEWS2: Market check: Stocks open lower, yield curve steepens, oil under pressure.NEWS3: Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1B.NEWS4: Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies.NEWS5: BeiGene to receive up to $1 billion in oncology deal with Novartis.NEWS6: Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab.NEWS7: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU).

Answer: Rise